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http://www.trialsjournal.com/content/14/1/204STUDY PROTOCOL Open AccessThe effect of nebulized salbutamol or isotonic
saline on exercise-induced bronchoconstriction in
elite skaters following a 1,500-meter race: study
protocol for a randomized controlled trial
Jean MM Driessen1*, Margryt Gerritsma1,2, Jaap Westbroek3, Nick HT ten Hacken4 and Frans HC de Jongh5,6Abstract
Background: Prevalence of exercise-induced bronchoconstriction (EIB) is high in elite athletes, especially after many
years training in cold and dry air conditions. The primary treatment of EIB is inhaling a short-acting beta-2-agonist
such as salbutamol. However, professional speed skaters also inhale nebulized isotonic saline or tap water before
and after a race or intense training. The use of nebulized isotonic saline or tap water to prevent EIB has not been
studied before, raising questions about safety and efficacy. The aim of this study is to analyze the acute effect of
nebulized isotonic saline or salbutamol on EIB in elite speed skaters following a1,500-meter race.
Methods: This randomized controlled trial compares single dose treatment of 1 mg nebulized salbutamol in 4 mL
of isotonic saline, or with 5 mL of isotonic saline. A minimum of 13 participants will be allocated in each treatment
group. Participants should be between 18 and 35 years of age and able to skate 1,500 m in less than 2 min 10 s
(women) or 2 min 05 s (men). Repeated measurements of spirometry, forced oscillation technique, and
electromyography will be performed before and after an official 1,500-m race. Primary outcome of the study is the
difference in fall in FEV1 after exercise in the different treatment groups. The trial is currently enrolling participants.
Discussion: Elite athletes run the risk of pulmonary inflammation and remodeling as a consequence of their
frequent exercise, and thus increased ventilation in cold and dry environments. Although inhalation of nebulized
isotonic saline is commonplace, no study has ever investigated the safety or efficacy of this treatment.
Trial registration: This trial protocol was registered with the Dutch trial registration for clinical trials under number
NTR3550.
Keywords: Elite athletes, Exercise-induced bronchoconstriction, Salbutamol, Forced oscillation technique,
Small airwaysBackground
Exercise-induced bronchoconstriction (EIB) is the most
common chronic condition in elite athletes [1]. Espe-
cially endurance athletes who reach high ventilation in
cold, dry air on a regular basis are susceptible to EIB
[1,2]. A study using a canine model highlighted the
negative effect of dry air on the airways as it leads to air-
way inflammation and airway remodeling [3]. In humans
this find has been confirmed in bronchial biopsies from* Correspondence: jean.driessen@tjongerschans.nl
1Sports Medicine, Tjongerschans Hospital, Heerenveen, the Netherlands
Full list of author information is available at the end of the article
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reproduction in any medium, provided the orcompetitive elite skiers, showing signs of eosinophilic
and neutrophilic airway inflammation in the lungs, simi-
lar to those seen in asthma [4].
In elite speed skaters intense training may cause tho-
racic pain and cause EIB [5]. For this reason many speed
skaters use a roll-collar in training to warm and humid-
ify inhaled air. Beuther et al. already showed that
warming the inhaled air can reduce EIB [6]. In competi-
tion, due to aerodynamics, this method cannot be used.
In an effort to reduce EIB and thoracic pain, inter-
national professional speed skaters nowadays inhale ne-
bulized isotonic saline or tap water before and after a racel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ment is a short-acting beta-2-agonist such as salbutamol
[1,7]. This treatment reduced smooth muscle contrac-
tion very effectively, but still is an example of symp-
tomatic therapy. The recommended dosage of nebulized
salbutamol is 5 mg, which would require a therapeutic
use exemption for participating athletes from the world
anti-doping agency (WADA) (www.wada-ama.org). Al-
though such a dosage is safe in highly trained athletes
[8], we routinely recommend using 1 mg of salbutamol,
which we believe leads to substantial reductions in EIB
in this population. The use of nebulized isotonic saline
treat EIB has not been studied before, raising questions
about safety and efficacy.
Spirometry before and after exercise is the golden
standard for assessing the occurrence and severity of
EIB [7]. A fall in forced expiratory volume in 1 s (FEV1)
>10%, after exercise (>95% predicted heart frequency)
indicates EIB. A potential disadvantage of spirometry is
the use of a forced maneuver and not everybody is able
to perform reliable measurements. In addition the man-
euver requires a forced deep inspiration which in asth-
matic children with EIB may lead to bronchodilation [9],
and an underestimation of EIB. The forced oscillation
technique (FOT) may be used to evaluate the patency of
the airways without the need of forced breathing [10].
Another substitute for evaluating lung function without
the need of forced breathing may be electromyography
(EMG), however, it has not been used to evaluate EIB
[11,12].
The aim of the study is to analyze the effect of nebu-
lized isotonic saline or salbutamol on EIB in elite speedMinimization:
Intense skating years(> 5 years) 
Use of inhaled corticosteroids
Placebo group: 
Skating 1500 meters
Nebulization of isotonic saline
Treatment group:
Skating 1500 meters








Figure 1 Timing if randomization and data collection of the study. EM




This study is a prospective, randomized, double-blind,
placebo, treatment, and non-intervention controlled
study, consisting of three parallel groups. Participants
will be randomized to receive either no intervention
(control), 1 mg of nebulized salbutamol (treatment), or
nebulized isotonic saline (placebo). An overview of the
timing of randomization and data collection can be seen
in Figure 1.
This trial protocol was ethically approved by the Re-
gional Ethical Committee (RTPO), Leeuwarden (pri-
mary) and the Central Committee on Research Involving
Human Subjects (CCMO), The Hague (secondary) and
was registered with the Dutch trial registration for cli-
nical trials (www.trialregister.nl) under number NTR
3550. All participants signed a written informed consent
form.
Setting and participants
Participants are recruited from the provincial selection
teams and professional skating teams in the Netherlands.
All skaters in these teams will be invited to participate in
the study after they will be screened for eligibility.
Inclusion criteria
Skaters should be between 18 and 35 years of age and be












10 minutes 20 minutes 30 minutes 
G, Electromyography; FOT, Forced oscillation technique; VAS, Visual
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lung function tests according to current standards [13].
Exclusion criteria
Skaters will be excluded if they had: a respiratory infection
within 6 weeks prior to the tests for which medication has
been prescribed; an FEV1 <70% of predicted; ultrasonic
nebulization with tap water or saline solutions within 48 h
before testing; use of short-acting beta agonists 8 h before
exercise; use of long-acting beta agonists 24 h before exer-
cise; use of a leukotriene-receptor-antagonist 36 h before
exercise.
Interventions
Four minutes after completing the 1,500-m race, the elite
skater will either inhale nebulized salbutamol (1 mg),
nebulized isotonic saline for 5 min or they will not receive
an intervention. An elite athlete inhaling nebulized tap
water can be seen in Figure 2. The dose of salbutamol,
1 mg, will be used to stay well below the WADA cutoff for
doping at an elite level of 1.6 mg daily. The route of
administration has been chosen to allow a viable com-
parison with nebulized saline [14]. Inhaled Salbutamol
has a longstanding record for treatment of bron-
choconstriction and poses a minimal risk for cardiovas-
cular complications even if used in dosages above the
recommended dosage [15]. The dosage used is below
the recommended dosage, furthermore, expert opinion
states that salbutamol has been used in higher dosages
immediately after extremely strenuous activity beforeAssess
eligibili
Random

































Figure 2 A flow diagram of the progress through the phases of the sand no adverse reactions have been reported. Further-
more, in a study by Elers et al., high dosages of inhaled
salbutamol were used to evaluate anabolic effects in well
trained athletes (VO2 max 66 mg∙ml∙min
-1). No benefi-
cial or harmful effects were seen on cardiopulmonary
function [8].
Pulmonary function measurements
FOT measurements will be performed with R.O.S.,
OscilinkW, SensormedicsW to measure general respira-
tory resistance and reactance. FOT measurements will
consist of three repeated measurements with nose
clipped and with hands supporting cheeks and base of
the mouth [10]. FOT measurements will be performed
before and at 10, 15, and 30 min after exercise. The ave-
rage of resistance and reactance values will be used for
statistical analysis.
A MasterscopeW JaegerW, will be used to measure
flow-volume loops in accordance with current ERS/ATS
guidelines [13]. Lung function will be calculated from
the best curve. Flow volumes will be measured in dupli-
cate before and at 11, 16, and 31 min after exercise, the
best values at each time point retained for analysis. Feeling
of dyspnea and thoracic pain will be evaluated using a
visual analogue scale (VAS) after every complete spi-
rometry measurement.
EMG of the diaphragm and intercostal muscles will be
derived transcutaneously from pairs of single electrodes
(disposable Neotrode, ConMed Corporation, NY) [11].
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margin in the nipple line (frontal lead of diaphragm) and
two bilaterally on the back at the same level (dorsal lead
of diaphragm). The mean value of the processed data of
the frontal and dorsal leads of the diaphragm repre-
sented the electrical activity of the whole diaphragm. A
common electrode will be placed at the height of the
sternum.Exercise provocation challenge
Exercise testing for measuring EIB will be performed
by skating 1,500 m. Cold, dry air will be obtained while
testing in the local skating ring, IJsbaan Thialf,
Heerenveen (http://www.thialf.nl).Outcomes
The primary outcome of the study is the difference in
percentage fall in FEV1 from baseline after exercise in
the different treatment groups. Secondary outcomes of
the study are the difference in airway resistance and
reactance in kPa/l/s at low frequency as measured with
the FOT and difference in diaphragm and intercostal
muscle activity in the logarithm of mean bottom ratio of
respiratory muscle activity between the different treat-
ment groups.Sample size
Numbers of study participants were calculated using the
calculations of Dupont, and setting power of the study
at 80% and P=0.05 [16]. Data used to produce these
numbers came from research performed by Driessen
et al. [17]. We expect no difference between placebo and
control groups. Analyzing the protective effect of salbu-
tamol in a randomized control trial, with an expected
difference in FEV1 of 10% and a standard deviation from
the mean of 6% the number of participants was set at 13
per group. Therefore the total number of randomized
participants will be at least 39. In the aforementioned re-
search performed by Driessen et al., 95% of patients
completed the study. Therefore the enrolled patient
count will be 1.05 times the total number (39•1.05=41).Randomization
Participants are randomized using a pre-generated
randomization list. For randomization a linear congruential
algorithm of Park and Miller with Bays-Durham shuffling
was employed, using block sizes of two, four, and eight
participants. Stratified minimization will commence using
the number of intensive training years (> or <5 years) and
the current use of asthma medication. A flow diagram of
the progress through the phases of the study can be seen
in Figure 1.Blinding
The study medication will be delivered to the skating
ring in a standard syringe, containing either 1 mg salbu-
tamol in isotonic saline or solely isotonic saline with a
standard label. The lack of inhalation in the control
group cannot be masked. Assessment of lung function
will be assessed without knowledge of the received
treatment.
Discontinuation
Participants can leave the study at any time for any rea-
son if they wish to do so without any consequences. The
investigator can decide to withdraw a participant from
the study for urgent medical reasons (for example, a fall
in FEV1 >25% from baseline). Discontinued participants
will not be replaced.
Data analysis
Best values of spirometric measurements, mean values
of FOT measurements and EMG measurements record-
ings of 60 s during FOT measurements will be used for
statistical calculations. Data will consist of a set of com-
paring participants who nebulized 1 mg Salbutamol, iso-
tonic saline, and one set of controls. Once gathered, data
will be analyzed with SPSS analytical software after test-
ing for normality with a Shapiro-Wilk test. Difference
between groups will be analyzed with a chi-square test
for dichotomous variables and a one-way ANOVA,
followed by a post-hoc Tukey’s test for continuous
variables.
Data storage
Data will be encoded in AccessW for windows. Traceable
participant data will be coded in a separate file, data
used in analysis will not be traceable to the participant
without the coding file. Data will be entered using the
double data entry format.
Discussion
This trial investigates a common procedure in elite ath-
letes. Elite athletes run the risk of pulmonary inflamma-
tion and remodeling as a consequence of their frequent
exercise, and thus increased ventilation in cold and dry
environments [3,4,7]. Although inhalation of nebulized
isotonic saline is commonplace, no study has ever inves-
tigated the safety or efficacy of this treatment.
Furthermore the pulmonary response to such an ex-
treme performance has not been investigated in such de-
tail, using not only spirometry and feeling of dyspnea,
but also the FOT and EMG of breathing musculature.
There are some limitations to this study. First and
foremost is the inclusion of the participants limited to
elite skaters. Not all speed skaters however will show a
substantial drop in FEV1 after exercise limiting the
Driessen et al. Trials 2013, 14:204 Page 5 of 6
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40% of elite speed skaters in the Netherlands will show a
substantial drop in FEV1 after exercise, this is even
higher than the percentage of American elite winter ath-
letes experiencing EIB [2]. Furthermore the inclusion of
the FOT and EMG measurements will allow more subtle
evaluation of pulmonary function, not disrupted by
forced breathing [9-11]. We will be able to analyze the
smaller airways using the extensive pulmonary function
measurements, however we preferred to also assess the
damage to pulmonary parenchyma using Clara Cell pro-
tein (CC16) [18]. We believe however that analyzing
CC16 in serum would have severely hampered the inclu-
sion rate of the participants.Trial status
The trial is currently enrolling participants and collects
data on three separate dates; all test dates will be official
races, approved by the Royal Dutch Skating organization
(www.knsb.nl). The first test date will be 21 December
2012. The second test date is planned in February 2013.
A third test date will be added in the fall of 2013. Data
analysis is expected to be completed in December 2013.
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